|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 114.48 CHF | +0.12% |
|
-1.33% | +4.49% |
| 08:52am | Europe's Key Companies – Telenor Jumps 8.1 Percent | FW |
| 01-21 | Zura Bio Appoints Sandeep Kulkarni as CEO | MT |
Business description: Novartis AG
- oncology (29.3%);
- immunology (18.5%);
- cardiovascular, renal and metabolic diseases (17%);
- neuroscience (9.4%).
The remaining net sales (25.8%) are from contract manufacturing of pharmaceutical products.
At the end of 2024, Novartis AG had over 30 production sites worldwide.
Net sales are distributed geographically as follows: Europe (30.9%), the United States (42%), Asia/Africa/Australasia (20%), Canada and Latin America (7.1%).
Number of employees: 75,883
Sales by Activity: Novartis AG
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
Innovative Medicines | 40.82B | 43.97B | 43.37B | 46.66B | 51.72B |
Sandoz | 9.89B | 9.87B | 9.48B | - | - |
Corporate (Including Eliminations) | -813M | -964M | -1.02B | - | - |
Geographical breakdown of sales: Novartis AG
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
United States | 16.48B | 16.82B | 17.65B | 17.96B | 21.15B |
Other | 19.04B | 20.81B | 20.05B | 15.87B | 18.51B |
China | 2.57B | 3.05B | 3.13B | 3.27B | 3.89B |
Germany | 4.52B | 4.87B | 4.28B | 3.37B | 3.66B |
France | 2.44B | 2.52B | 2.26B | 1.75B | 1.79B |
Switzerland | 800M | 873M | 970M | 1.31B | 1.32B |
Japan | 2.8B | 2.68B | 2.2B | 1.92B | - |
Executive Committee: Novartis AG
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 31/01/2018 | |
| Director of Finance/CFO | 61 | 23/04/2013 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 64 | 15/05/2022 |
Karen Hale
CMP | Compliance Officer | 58 | 13/04/2025 |
Steffen Lang
COO | Chief Operating Officer | 59 | 03/04/2022 |
Composition of the Board of Directors: Novartis AG
| Director | Title | Age | Since |
|---|---|---|---|
Nancy Andrews
BRD | Director/Board Member | 67 | 31/12/2014 |
Liz Doherty
BRD | Director/Board Member | 69 | 31/12/2015 |
Ton Büchner
BRD | Director/Board Member | 61 | 31/12/2015 |
Frans van Houten
BRD | Director/Board Member | 65 | 27/02/2017 |
Patrice Bula
BRD | Director/Board Member | 70 | 27/02/2019 |
Bridgette Heller
BRD | Director/Board Member | 64 | 27/02/2020 |
Simon Moroney
BRD | Director/Board Member | 67 | 27/02/2020 |
| Director/Board Member | 59 | 03/03/2022 | |
| Director/Board Member | 66 | 03/03/2022 | |
John Young
BRD | Director/Board Member | 62 | 06/03/2023 |
Holdings: Novartis AG
| Name | Equities | % | Valuation |
|---|---|---|---|
NOVARTIS AG 7.04% | 148,621,654 | 7.04% | 20 594 M $ |
NOVARTIS INDIA LIMITED 70.68% | 17,450,680 | 70.68% | 151 M $ |
ERASCA, INC. 4.34% | 12,307,692 | 4.34% | 46 M $ |
MOLECULAR PARTNERS AG 4.31% | 1,739,130 | 4.31% | 7 M $ |
| 413,581 | 3.51% | 2 M $ |
Company details: Novartis AG
Group companies: Novartis AG
| Name | Category and Sector |
|---|---|
Novartis Healthcare Pvt Ltd.
 Novartis Healthcare Pvt Ltd. Manufactures and markets health care and nutritional products | |
Pharmaceuticals: Major
| |
Pharmaceuticals: Major
| |
EBEWE Pharma Ges.m.b.H. Nfg.KG
 EBEWE Pharma Ges.m.b.H. Nfg.KG Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products |
Pharmaceuticals: Major
|
EBEWE Pharma Ges.m.b.H. Nfg.KG
EBEWE Pharma Ges.m.b.H. Nfg.KG Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products |
Pharmaceuticals: Major
|
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.12% | -1.33% | +28.16% | +34.05% | 276B | |
| +3.58% | +0.49% | +45.28% | +211.65% | 966B | |
| -0.09% | -0.25% | +47.15% | +29.20% | 525B | |
| +0.99% | -2.59% | +25.22% | +44.49% | 382B | |
| +0.57% | +0.76% | +28.31% | +17.35% | 371B | |
| +1.12% | -6.01% | +22.01% | +22.16% | 278B | |
| +1.52% | +0.09% | +15.45% | +1.06% | 276B | |
| +3.52% | +2.26% | -32.57% | -19.88% | 260B | |
| +3.81% | +4.45% | +25.03% | +30.53% | 185B | |
| +4.00% | +4.06% | +38.89% | +55.54% | 160B | |
| Average | +0.91% | -0.33% | +24.29% | +42.62% | 367.94B | |
| Weighted average by Cap. | +0.43% | -0.48% | +29.67% | +72.94% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVN Stock
- Company Novartis AG
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition